R
34.86
0.35 (1.01%)
| 前收盘价格 | 34.51 |
| 收盘价格 | 34.74 |
| 成交量 | 106,265 |
| 平均成交量 (3个月) | 5,969,519 |
| 市值 | 25,073,766,400 |
| 价格/销量 (P/S) | 2.90 |
| 股市价格/股市净资产 (P/B) | 5.49 |
| 52周波幅 | |
| 利润日期 | 10 Aug 2026 |
| 营业利益率 (TTM) | -4,823.84% |
| 稀释每股收益 (EPS TTM) | -0.750 |
| 季度收入增长率 (YOY) | -16.10% |
| 季度盈利增长率 (YOY) | -96.70% |
| 总债务/股东权益 (D/E MRQ) | 1.93% |
| 流动比率 (MRQ) | 33.47 |
| 营业现金流 (OCF TTM) | -839.45 M |
| 杠杆自由现金流 (LFCF TTM) | -375.20 M |
| 资产报酬率 (ROA TTM) | -10.73% |
| 股东权益报酬率 (ROE TTM) | -12.54% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Roivant Sciences Ltd. | 混合的 | 看涨 |
AIStockmoo 评分
0.7
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.5 |
| 平均 | 0.67 |
|
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Large Core |
| 内部持股比例 | 30.31% |
| 机构持股比例 | 83.49% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Qvt Financial Lp | 31 Mar 2026 | 25,161,237 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合